Determinants of progression in idiopathic pulmonary fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 149, Issue 2 I, 1994, Pages 444-449

  Schwartz, David A ^a   Van Fossen, D Scott ^a   Davis, Charles S ^a   Helmers, Richard A ^a   Dayton, Charles S ^a   Burmeister, Leon F ^a   Hunninghake, Cary W ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; FEMALE; FIBROSING ALVEOLITIS; GAS EXCHANGE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG FIBROSIS; LUNG FUNCTION; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TOTAL LUNG CAPACITY;

EID: 0028091361     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.149.2.8306043     Document Type: Article

References (46)

1. Fulmer JD, Roberts WC, Von Gal EW, Crystal RG. Morphologic-physiologic correlates of the severity of fibrosis and degree of cellularity in idiopathic pulmonary fibrosis. J Clin Invest 1979; 63:665-76.
2. Pande JN. Interrelationship between lung volume, expiratory flow, and the lung transfer factor in fibrosing alveolitis. Thorax 1981; 36:858-62.
3. Cherniack RM, Crystal RG, Kalica AR. Current concepts in idiopathic pulmonary fibrosis: a road map for the future. Am Rev Respir Dis 1991; 143:680-3.
4. Carrington CB, Gaensler EA, Coutu RE, Fitzgerald MX, Gupta RG. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298:801-9.
5. Turner-Warwick M, Burrow B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980; 35:171-80.
6. Tukiainen P, Taskinen E, Holsti P, Korhola O, Valle M. Prognosis of cryptogenic fibrosing alveolitis. Thorax 1983; 38:349-55.
7. Stack BHR, Choo-Kang YFJ, Heard BE. The prognosis of Cryptogenic fibrosing alveolitis. Thorax 1972; 27:535-42.
8. Rudd RM, Haslam PL, Turner-Warwick M. Cryptogenic fibrosing alveolitis. Am Rev Respir Dis 1981; 124:1-8.
9. Livingstone JL, Lewis JG, Reid L, Jefferson KE. Diffuse interstitial pulmonary fibrosis. Quart J Med 1964; 33:71-103.
10. Hiwatari N, Shimura S, Sasaki T, Aikawa T, Ando Y, Ishihara H, Sekizawa K, Sasaki H, Takishima T. Prognosis of idiopathic pulmonary fibrosis in patients with mucous hypersecretion. Am Rev Respir Dis 1991; 143:182-5.
11. Schwartz DA, Helmers RA, Galvin JR, Van Fossen DS, Frees KL, Dayton CS, Burmeister LF, Hunninghake GW. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149: 450-4.
12. Turner-Warwick M, Haslam PL. The value of serial bronchoalveolar lavages in assessing the clinical progress of patients with Cryptogenic fibrosing alveolitis. Am Rev Respir Dis 1987; 135:26-34.
13. Watters LC, Schwarz MI, Cherniack RM, Waldron JA, Dunn TL, Stanford RE, King TE. Idiopathic pulmonary fibrosis: pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis 1987, 135:696-704.
14. Haslam PL, Turton GWG, Heard B, Lukoszek A, Collins JV, Salsbury AJ, Turner-Warwick M. Bronchoalveolar lavage in pulmonary fibrosis: comparison of cells obtained with lung biopsy and clinical features. Thorax 1980; 35:9-18.
15. Peterson MW, Monick M, Hunninghake GW. Prognostic role of eosinophils in pulmonary fibrosis. Chest 1987; 92:51-6.
16. Schwanz DA, Helmers RA, Dayton CS, Merchant RK, Hunninghake GW. Determinants of bronchoalveolar lavage cellularity in idiopathic pulmonary fibrosis. J Appl Physiol 1991; 71:1688-93.
17. Schwanz DA, Merchant RK, Helmers RA, Gilbert SR, Dayton CS, Hunninghake GW. The influence of cigarette smoking on lung function in patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1991; 144:504-6.
18. Hanley ME, King TE, Schwarz MI, Watters LC, Shen AS, Cherniack RM. The impact of smoking on mechanical properties of the lungs in idiopathic pulmonary fibrosis and sarcoidosis. Am Rev Respir Dis 1991; 144:1112-6.
19. Leibow AA, Carrington CB. The interstitial pneumonias. In: Simon M, ed. Frontiers in pulmonary radiology. New York: Grune and Stratton, 1968; 102-41.
20. American Thoracic Society Statement. Snowbird workshop on standardization of spirometry. Am Rev Respir Dis 1979; 119:831-8.
21. Morris JF, Koski A, Johnson LC. Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis 1971; 103:57-67.
22. Goldman HI, Becklake MR. Respiratory function tests: normal values at median altitudes and the prediction of normal results. Am Rev Tuberc 1959; 79:457-67.
23. Van Ganse WF, Ferris BG, Cotes JE. Cigarette smoking and pulmonary diffusing capacity (transfer factor). Am Rev Respir Dis 1972; 105:30-41.
24. American Medical Association. Guides to the evaluation of permanent impairment. Chicago: AMA, 1989.
25. Renzetti AD, Bleeker ER, Epler GR, Jones RN, Kanner RE, Repsher LH. Evaluation of impairment/disability secondary to respiratory disorders. Am Rev Respir Dis 1986; 133:1205-9.
26. International Labor Organization. International classification of radiographs of pneumoconioses: guidelines for the use of International Labor Organization (ILO). Geneva: International Labor Office, 1980.
27. Zavala DC, Hunninghake GW. Lung lavage. In: Fleney DC, Petty TL, eds. Recent advances in respiratory medicine. Vol. 3. Edinburgh: Churchill Livingston, 1983; 21-33.
28. Zerger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121-30.
29. Davis CS. A computer program for regression analysis of repeated measures using generalized estimating equations. Comput Methods Programs Biomed 1993; 40:15-31.
30. Kleinbaum DG, Kupper LL. Applied regression analysis and other multivariate methods. Boston, MA: Duxbury, 1978.
31. Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules: applications and methodological standards. N Engl J Med 1985; 313:793-9.
32. Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE, Cherniack RM. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986; 133:97-103.
33. Killian KJ, Campbell EJ. Dyspnea and exercise. Ann Rev Physiol 1983; 45:465-79.
34. Simon PM, Schwartzstein RM, Weiss JW, Fencl V, Teghtsoonian M, Weinberger SE. Distinguishable types of dyspnea in patients with shortness of breath. Am Rev Respir Dis 1990; 142:1009-14.
35. Bergner M, Bobbitt RA, Kressel S, Pollard WE, Gilson BS, Morris JR. The Sickness Impact Profile: conceptual formulation and methodology for the development of a health status measure, Int J Health Serv 1976; 6:393-415.
36. Bergner M, Bobbitt A, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19:787-805.
37. Bergner M. Quality of life, health status, and clinical research. Med Care 1989; 27:S148-56.
38. Schwanz DA, Galvin JR, Merchant RK, Dayton CS, Burmeister LF, Merchant JA, Hunninghake GW. The influence of cigarette smoking on bronchoalveolar lavage cellularity in asbestos-induced lung disease. Am Rev Respir Dis 1992; 145:400-5.
39. Blanc PD, Golden JA, Gamsu G, Aberle DR, Gold WM. Asbestos exposure-cigarette smoking interactions among shipyard workers. JAMA 1988; 259:370-3.
40. Hunninghake GW, Fauci AS. Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis 1979; 119:471-503.
41. Barbers RG, Gong H, Takhkin DP, Oishi J, Wallace JM. Differential examination of bronchoalveolar lavage cells in tobacco cigarette and marijuana smokers. Am Rev Respir Dis 1987; 135:1271-5.
42. Harris JO, Swenson EW, Johnson JE. Human alveolar macrophages: comparison of phagocytic ability, glucose utilization, and ultrastructure in smokers and nonsmokers. J Clin Invest 1970; 49:2086-96.
43. Gadek JE, Fells GA, Crystal RG. Cigarette smoking induces functional antiprotease deficiency in the lower respiratory of humans. Science 1979; 206:1315-6.
44. Merrill WW, Goodenberger D, Strober W, Matthay RA, Nagel GP, Reynolds HY. Free secretary component and other proteins in human lung lavage. Am Rev Respir Dis 1980; 122:156-61.
45. Villiger B, Broekelmann T, Kelley D, Heymach GJ, McDonald JA. Bronchoalveolar fibronectin in nonsmokers and smokers Am Rev Respir Dis 1981; 124:652-4.
46. McFadden D, Wright JC, Wiggs B, Churg A. Cigarette smoke increases the penetration of asbestos fibers in airway walls. Am J Pathol 1986; 123:95-9.